{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:13:07Z","timestamp":1790485987121,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"DOI":"10.1097\/qad.0b013e328351997f","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T04:28:29Z","timestamp":1329193709000},"page":"1073-1082","source":"Crossref","is-referenced-by-count":35,"title":["Overall benefit of antiretroviral treatment on the risk of fracture in HIV"],"prefix":"10.1097","volume":"26","author":[{"given":"Linda M.","family":"Mundy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada O.","family":"Youk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace A.","family":"McComsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve J.","family":"Bowlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/COH.0b013e32833860e9","article-title":"The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008.","volume":"5","author":"Beck","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"R2-3-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QCO.0b013e328334fe9a","article-title":"HIV and bone mineral density.","volume":"23","author":"Mallon","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"R3-3-20210130","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00002030-200104130-00005","article-title":"Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight preantiretroviral therapy.","volume":"15","author":"Carr","year":"2001","journal-title":"AIDS"},{"key":"R4-3-20210130","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/00002030-200107060-00009","article-title":"Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir.","volume":"15","author":"Nolan","year":"2001","journal-title":"AIDS"},{"key":"R5-3-20210130","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1210\/jc.2006-0127","article-title":"Longitudinal analysis of bone density in human immunodeficiency virus-infected women.","volume":"91","author":"Dolan","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-3-20210130","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.","volume":"20","author":"Brown","year":"2006","journal-title":"AIDS"},{"key":"R7-3-20210130","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1210\/jc.2007-1660","article-title":"Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis.","volume":"92","author":"Bolland","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-3-20210130","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/QAD.0b013e32832c1792","article-title":"Continuous antiretroviral therapy decreases bone mineral density.","volume":"23","author":"Grund","year":"2009","journal-title":"AIDS"},{"key":"R9-3-20210130","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/QAD.0b013e32832c4947","article-title":"First line zidovudinelamivudinelopinavirritonavir leads to greater bone loss compared to nevirapinelopinavirritonavir.","volume":"23","author":"van Vonderen","year":"2009","journal-title":"AIDS"},{"key":"R10-3-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R11-3-20210130","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0b013e3181adce44","article-title":"Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.","volume":"51","author":"Brown","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-3-20210130","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/QAD.0b013e328328f789","article-title":"Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.","volume":"23","author":"Duvivier","year":"2009","journal-title":"AIDS"},{"key":"R13-3-20210130","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1210\/jc.2008-0828","article-title":"Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system.","volume":"93","author":"Triant","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-3-20210130","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1086\/501015","article-title":"HIV infection and bone mineral density in middle-aged women.","volume":"42","author":"Arnsten","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R15-3-20210130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/QAD.0b013e3280148c05","article-title":"Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection.","volume":"21","author":"Arnsten","year":"2007","journal-title":"AIDS"},{"key":"R16-3-20210130","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1086\/656412","article-title":"Bone disease in HIV infection: a practical review and recommendations for HIV care providers.","volume":"51","author":"McComsey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R18-3-20210130","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00043764-199804000-00010","article-title":"OCMAP-PLUS: a new program for the comprehensive analysis of occupational cohort data.","volume":"40","author":"Marsh","year":"1998","journal-title":"J Occup Environ Med"},{"key":"R20-3-20210130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.22294","article-title":"Fracture risk with intermittent high-dose oral glucocorticoid therapy.","volume":"56","author":"De Vries","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R21-3-20210130","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/clpt.2009.267","article-title":"The challenge of complexity.","volume":"88","author":"Dollery","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R22-3-20210130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1310\/hct0803-164","article-title":"The safety and efficacy of tenofovir DR in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1 infected patients.","volume":"8","author":"Cassetti","year":"2007","journal-title":"HIV Clinical Trials"},{"key":"R23-3-20210130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamuvidine versus tenofovier-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R24-3-20210130","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224, a substudy of ACTG A5202.","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"R25-3-20210130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1086\/341489","article-title":"Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.","volume":"35","author":"Dube","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R26-3-20210130","first-page":"e5","article-title":"Short-term bone loss in HIV-infected premenopausal women.","volume":"54","author":"Yin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R27-3-20210130","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.2337\/dc10-0633","article-title":"Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.","volume":"33","author":"Brown","year":"2010","journal-title":"Diab Care"},{"key":"R28-3-20210130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/QAI.0b013e318189a794","article-title":"Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy.","volume":"49","author":"Ross","year":"2008","journal-title":"JAcquir Immune Defic Syndr"},{"key":"R30-3-20210130","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1097\/QAD.0b013e32833f6294","article-title":"Fracture incidence in HIV-infected women: results from the Womens Interagency HIV Study.","volume":"24","author":"Yin","year":"2010","journal-title":"AIDS"},{"key":"R31-3-20210130","doi-asserted-by":"crossref","first-page":"e17217","DOI":"10.1371\/journal.pone.0017217","article-title":"Increased risk of fragility fractures among HIV infected compared to uninfected male veterans.","volume":"6","author":"Womack","year":"2011","journal-title":"PLoS One"},{"key":"R32-3-20210130","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/cid\/ciq242","article-title":"HIV Outpatient Study (HOPS) InvestigatorsIncreased rates of bone fracture among hiv-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006.","volume":"52","author":"Young","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R33-3-20210130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/QAI.0b013e31821ecf4c","article-title":"Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients.","volume":"57","author":"Yong","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R34-3-20210130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1210\/jc.2003-030767","article-title":"Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated HIV-infected children.","volume":"89","author":"Mora","year":"2004","journal-title":"J Clin Endocrinol Metab"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAD.0b013e328351997f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:38:41Z","timestamp":1786048721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201206010-00003"}},"subtitle":["nested case\u2013control analysis in a health-insured population"],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328351997f","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6,1]]}}}